NuPathe, Inc.

Nenad Grmusa was “really happy” at Takeda , where he’d been for more than a decade in various R&D strategy and finance positions. However, the more he learned about DEM BioPharma , the more intrigued he became by cancer’s unexplored “don’t eat me” signals. Jonathan Weissman and team launched the aptly-named biotech back in June to deploy macrophages and other myeloid effector cells against tumors by using so-called “don’t eat me” and “eat me” signals, which allow cancer cells to evade the immune system. The Longwood -backed startup officially tapped Grmusa as CEO on Thursday, alongside Oncorus vet Christophe Quéva , who’s joining as CSO. Quéva’s resume boasts stints at iTeos , as well as AstraZeneca , Amgen and Gilead . The team also took the opportunity to introduce Loise Francisco-Anderson , who recently joined as VP and head of biology. “I was amazed how much data the group has generated in such a short period of time and I’m really really impressed by the quality of the scientific team,” Grmusa said. He’s taking over from founding CEO David Donabedian , who will continue to advise the company. Former Trillium Therapeutics CEO Jan Skvarka is also on board as executive chairman. Upon launching with a $70 million Series A, Donabedian predicted that the company might be in the clinic in the next two to three years. Grmusa confirmed that timeline on Thursday, adding that the company is hoping to get IND-enabling studies under its belt by 2024. The startup’s platform, dubbed Co-culture with Human Myeloid Phagocytes or CHoMP, seeks targets using CRISPR screening. The team is currently 15-large, though Grmusa added that the company’s looking to grow. “It’s been a very short period of time, but we’ve recruited the top scientific talent, and I’m amazed,” he said. Grmusa’s background is in finance and economics, where he graduated from the Brandeis International Business School with his master’s. He later held analyst positions at Boston Biomedical Consultants and Millennium Pharmaceuticals , before jumping to Takeda in 2012. Most recently, he was SVP of R&D strategy and external innovation, and CFO of R&D. — Nicole DeFeudis → Greg Mayes has bolted from Antios Therapeutics , taking over from Joseph del Moral as president and CEO of Toronto psychedelics biotech Reunion Neuroscience . On Mayes’ watch, Antios pulled together a $96 million raise in April 2021 and another $75 million in November to form its Series B, but the biotech ran into trouble a few months ago when the FDA threw down the stop sticks with a clinical hold on its HBV drug. Assembly Biosciences would pull the plug on its collaboration with Antios as a result. As del Moral becomes chairman, Mayes now leads a company once known as Field Trip Health with its lead program RE-104 in early-stage trials for treatment resistant depression and a Phase II planned in August 2023 for postpartum depression. “My goal as president and CEO of Reunion is to lead a company that will boldly disrupt the mental health sector with differentiated serotonergic psychedelic therapies,” Mayes said in a statement. → The changes are pronounced at GSK as the pharma giant consciously brands itself as the “New GSK,” spinning off its consumer healthcare business while placing a premium on specialty medicine and vaccine R&D. You can also sense it with the leadership team: R&D chief Hal Barron is gone, landing a CEO gig at the ambitious anti-aging play Altos Labs , and now CFO Iain Mackay has decided to retire in May 2023. Mackay will be replaced by Julie Brown , the chief operating and financial officer at Burberry who spent a quarter-century with AstraZeneca in a number of executive roles, including interim CFO and VP of group finance. Effective immediately, Brown has left the board of directors at Roche , and Patrick Frost will replace her temporarily as chair of the Swiss pharma’s audit committee. Amber Tong has more on Brown’s appointment . → Using its Covid-19 jab as a springboard for more potential vaccine launches — cytomegalovirus and the flu among them — Stéphane Bancel will give Juan Andres a new role on Jan. 1 at Moderna , naming him president, strategic partnerships and enterprise expansion. Jerh Collins , a 30-year Novartis vet who has been the Big Pharma’s chief culture officer since September 2020, will replace Andres as chief technical operations and quality officer, and will join the mRNA biotech three months early on Oct. 3. Andres has ties to Novartis himself, serving as global head of technical operations there until he took off for Moderna as SVP of late-stage technical development and manufacturing in August 2017. → Fred Kamal has been promoted to president and COO of 4D Molecular Therapeutics , the Emeryville, CA gene therapy biotech with programs that go after wet AMD, Fabry disease and cystic fibrosis. Kamal, the operations chief since February 2020, came to 4DMT in the fall of 2018 as chief technical officer after stints at InterMune , Juno Therapeutics and Avexis . UCSF professor Noriyuki Kasahara , principal investigator at the school’s Brain Tumor Center, has claimed a spot on 4DMT’s board of directors. → Takeda partner KSQ Therapeutics has promoted head of immunology Micah Benson to CSO and has recruited Tom Leitch as chief technology officer. Benson was head of tolerance therapeutics for Pfizer ’s immunology and inflammation research unit, then signed on as KSQ’s head of immuno-oncology in 2016. An 11-year Merck vet who held leadership roles at Alexion , Leitch is the latest to peel away from bluebird bio in the wake of its two gene therapy approvals, moving on to KSQ after two years as bluebird’s head of manufacturing and five years overall. Additionally, Dunad Therapeutics chief Pearl Huang is leaving the board of directors, while Benson’s predecessor Frank Stegmeier steps in to keep it a six-member board. → Dave Anderson has been named CSO of Philadelphia’s Code Biotherapeutics , the gene therapy outfit led by former GSK exec Brian McVeigh that made Takeda stand up and take notice with a $2 billion AAV deal in February. Anderson once led preclinical research for neurological diseases at Spark and had just been promoted to SVP of research at SwanBio in June. Code has competition with the non-viral approach, as biotechs like Xalud Therapeutics and Versant -backed Vector BioPharma jockey for position. → New Zentalis CEO Kim Blackwell is continuing to tinker with the leadership around her, promoting co-founder Kevin Bunker to CSO after swinging the door open for medical chief Carrie Brownstein last week and elevating another co-founder , Cam Gallagher , to president in her first couple weeks on the job. A former senior scientist in Pfizer’s drug discovery research group, Bunker — heretofore the COO at Zentalis — co-founded and was CSO of Kalyra Pharmaceuticals . → What about Brownstein’s successor at her former employer? Cellectis is looking inward for that, as Mark Frattini moves into the CMO slot . Frattini pivoted to Cellectis in August 2020 as SVP of clinical sciences after his turn as executive medical director, program lead, global clinical R&D in the hematology therapeutic area for Celgene and Bristol Myers Squibb . “Mark already had an impressive track record before joining Cellectis,” CEO André Choulika said in a statement. “He has continued to lead our clinical teams successfully over the last two years and I am thrilled to continue working with him in this expanded role.” → Vancouver-based Gandeeva Therapeutics , a cryogenic electron microscopy (cryo-EM) biotech that notched a $40 million Series A in January from the likes of Leaps by Bayer and Amgen, has selected Matthew Lucas as CSO and David Poon as CBO. Lucas, the ex-senior director of chemistry at Yumanity , closed out his three years at Black Diamond as SVP of drug discovery, while Poon is a 15-year Zymeworks vet who was recently the heavily restructured company’s VP, business development and alliance management. → After eFFECTOR Therapeutics plucked new CMO Douglas Warner from Amgen in August, Mayank Gandhi has replaced Alana McNulty as CBO of the California cancer biotech. In 2020, Gandhi jumped on the now-rickety SPAC bandwagon as VP of corporate development & strategy at Jiya Acquisition Corp , the blank check company set up by Srini Akkaraju . Earlier, he concluded a seven-year run at Genentech as business development & licensing director. → Rick Klausner ’s T cell therapy shop Lyell Immunopharma has appointed Rahsaan Thompson as chief legal officer. Thompson is an Actelion legal vet who moves on to Lyell following his two years as Gritstone bio ’s general counsel, and it’s the second big C-suite pickup for Lyell this year: Gary Lee jumped on board as CSO in late January . Klausner sold 11,100 shares of Lyell’s stock last Friday, with an uptick in the stock price $LYEL most of this week. → Led by former Seagen exec Nancy Whiting and Blueprint Medicines alums, San Diego’s Recludix Pharma has entrusted Matthew Caldemeyer with CBO duties. Caldemeyer just spent four years in business development at Everest Medicines — now under new management — and the Eli Lilly vet has also built his BD résumé with Amgen, Array BioPharma and Ambrx . Recludix pulled off the tarp in November 2021 with a $60 million Series A as the crew takes aim at STAT3 and STAT6. → RNA editing upstart ADARx Pharmaceuticals has tapped Christopher Prentiss as CFO. The former finance chief at Adamas Pharmaceuticals comes to a biotech that made a splash a year ago with a $75 million Series B in a space that also includes Shape Therapeutics and ProQR . Prentiss has prior finance experience in the industry with InterMune, Dynavax and MannKind . → Fresh off its £48.3 million ($56.57 million) acquisition of Diurnal Group a month ago, Neurocrine has promoted Ingrid Delaet to chief regulatory officer. Delaet had been VP of regulatory affairs since January 2021, and she was SVP, regulatory affairs at Intercept before her move to Neurocrine. In 19 years with Bristol Myers, she worked in clinical R&D and was therapeutic area lead for immunology within global regulatory affairs. → Cambridge, UK-based Mursla has welcomed Karin Schmitt to its leadership team as COO. Schmitt brings with her a wealth of experience from previous stints at Exelixis , Millennium Pharmaceuticals, Thermo Fisher Scientific , Horizon Discovery Group , PredictImmune and Mogrify . → Larry Green is seizing the reins once again at AlivaMab Discovery Services , taking over from Justin Mika . Green was the founding CEO of the San Diego-based company and has served as AlivaMab’s executive chair since May 2020. Earlier in his career, Green served in roles at Amgen and Abgenix among others. Green also wears the CEO hat at Ablexis and will continue to serve in his role there. → California VC Section 32 has plugged in Nick Smith as chief investor relations officer. Smith had led investor relations at Foresite Capital since 2018, and in another recent stop, he was director and regional head of client advisory for Winton Group . → Just as we were publishing last week’s Peer Review, T cell engager player Janux Therapeutics welcomed Brenda Van Vreeswyk as head of human resources. Van Vreeswyk was director of HR during a six-year stay at Neurocrine before moving on to the Merck partner, which also added Winston Kung to its board of directors last week. → Insmed CEO and Aegerion co-founder Will Lewis has been named chairman of Adrestia Therapeutics , a GSK-backed “synthetic rescue” biotech out of Cambridge, UK. Adrestia also has a pair of new execs: Jennifer Millian (VP of US operations) had a nearly 16-year association with Sanofi Genzyme before joining uniQure as director, program management, and she was recently VP of program and alliance management for Affinia Therapeutics . And Phil Coxon (VP of business development) ascended to senior director of transactions in global oncology business development and licensing at AstraZeneca last year, after joining the Big Pharma from Teva in 2018. → Inflammation-focused RAPT Therapeutics has brought in Jennifer Nicholson as SVP of regulatory affairs and quality assurance, and Adnan Rahman as VP of commercial. Nicholson makes her way to RAPT from Kronos Bio , where she was VP of regulatory affairs, and she’s held regulatory positions at Roche/Genentech, Jazz Pharmaceuticals , Bavarian Nordic and Acerta Pharma . Rahman, meanwhile, steps away from his gig as global commercial lead of dermatology at Pfizer sub Arena Pharmaceuticals . Earlier, he wrapped up a 16-year career at Amgen as US commercial director of the bone drug Xgeva . → In Phase II trials with its MK2 inhibitor zunsemetinib for rheumatoid arthritis, psoriatic arthritis and hidradenitis suppurativa, Aclarus Therapeutics has enlisted Robert Doody as VP, investor relations. He just held the same title at Provention Bio and is the former SVP of investor relations & corporate communications at Idera Pharmaceuticals . → Swiss-based Pureos Partners has tapped Veronica Gambillara Fonck as a new partner. Fonck has served in roles at GlycoVaxyn , was CEO and co-founder of LimmaTech and CEO and founder of GlycoEra . → Affinivax’s former CBO Stuart Chaffee is making his way to the board of directors at Olaris to become executive chairman. Chaffee’s prior experience includes gigs at Praxis Precision Medicines (CBO and CFO), Atlas Venture (entrepreneur in residence), Kymera Therapeutics (head of business operations), Amgen and Biogen. → Ex- Santen chief Adrienne Graves is headed to the board of directors at retinal disease biotech Opus Genetics , joining its scientific founder Jean Bennett , Opus CEO Ben Yerxa and Russell Kelley from the Foundation Fighting Blindness. Graves chairs the FFB’s Retinal Degeneration Fund and is a board member at Iveric Bio . → Princeton, NJ-based cancer player Sonnet BioTherapeutics has elected Lori McNeill to the board of directors. During her career at Pfizer from 2001-14, McNeill was chief of staff of global operations in the integrated health business unit. → Grappling with its Phase III fail with lenabasum and turning its attention to preclinical solid tumor candidate CRB-601 , Corbus Pharmaceuticals has reserved a seat for Anne Altmeyer on the board of directors. The ex-CBO of Sigilon Therapeutics and Adicet Bio is the president and CEO of TigaTx . → US-Danish biotech Allarity Therapeutics has pulled out a seat on its board for Jerry McLaughlin . McLaughlin currently serves as CEO and board member of Life Biosciences . McLaughlin’s previous stints include roles at Neos Therapeutics (CEO and president), NuPathe , Endo Pharmaceuticals and Merck. McLaughlin’s appointment comes on the heels of the company dropping its cancer drug dovitinib from development after the FDA requested a new trial. → Frazier Life Sciences managing director James Topper is back on the board of directors at Phathom Pharmaceuticals , the Takeda spinout and vonoprazan developer co-created by Frazier. Topper, the chairman and CEO of Frazier Lifesciences Acquisition Corporation , was a board member at Phathom from 2018-21. Special thanks to artist Kim Ryu for giving Peer Review a new look starting this week!

Cambridge, MA U.S.A. (September 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the appointment of Jerry McLaughlin as a new member of its Board of Directors, effective October 1, 2022. Mr. McLaughlin is a highly accomplished biotechnology executive with extensive experience in financing, drug development, licensing, commercialization, and product lifecycle management. Mr. McLaughlin is expected to serve on the compensation, and audit committees as an independent director. “I am delighted that Jerry has chosen to join Allarity’s board at this crucial time in our evolution,” said Dr. Duncan Moore, Allarity’s Chairman of the Board. “His operational experience in clinical stage therapeutic development and capital markets acumen will be of great value as we continue to implement the Company’s combination therapy-focused strategy.” Mr. McLaughlin said: “I firmly believe Allarity Therapeutics is in a unique position to become a leader within the personalized medicinespace by developingnovel combination oncology therapies together with the Company’s unique DRP®companion diagnostics. Allarity’s recent strategic shiftis aligned with the ongoing patient and market realities in oncology, as we continue to see substantially higher patient benefits with combination therapies. I look forward to supporting the CEO, Jim Cullem, and the rest of the Allarity team in unlocking both the clinical and commercial potential of this strategy.” Mr. McLaughlin has three decades of experience in leading operational and executive management roles. He made key contributions to significant life science milestones, including product launches, acquisitions, and financings. He is currently serving as CEO and Board Member of Life Biosciences, LLC, a development-stage biopharmaceutical company advancing therapeutics for patients with neurological and psychiatric diseases. Prior to serving in this role, he was President, CEO, and Member of the Board of Directors at Neos Therapeutics (acquired by Aytu BioScience.) Before joining Neos Therapeutics, he served as President, CEO, and Member of the Board of Directors at AgeneBio, Inc. Earlier in his career, he held corporate leadership roles at NuPathe, Inc., Endo Pharmaceuticals Inc., and Merck & Co., Inc. He received his B.A. from Dickinson College and his MBA from Villanova University in Pennsylvania. About AllarityTherapeutics Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP® platform. The Company has a mature portfolio of three drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer; dovitinib, a post-Phase 3 pan-tyrosine kinase inhibitor; and the European rights to IXEMPRA® (Ixabepilone), a microtubule inhibitor approved in the U.S. and marketed by R-PHARM U.S. for the treatment of second-line metastatic breast cancer, currently in Phase 2 development in Europe for the same indication. Additionally, the Company has rights in two secondary assets: 2X-111, a liposomal formulation of doxorubicin in Phase 2 development for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured out-license to Smerud Medical Research International AS; and LiPlaCis®, a liposomal formulation of cisplatin and its accompanying DRP®, being developed via a partnership with Chosa ApS, an affiliate of Smerud Medical Research International, for late-stage metastatic breast cancer. The Company is headquartered in the United States and maintains an R&D facility in Hoersholm, Denmark. For more information, please visit the Company’s website at About the Drug Response Predictor – DRP® Companion Diagnostic Allarity uses its drug-specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high DRP® score, the therapeutic response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP® is based on messenger RNA from patient biopsies. The DRP® platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined (both retrospective and prospective), including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA®. The DRP® platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in peer reviewed literature. Follow Allarity on Social Media Facebook: LinkedIn: Twitter: Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Allarity’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements related to clinical and commercial potential due to the Company advancing dovitinib in combination with another therapeutic candidate or other approved drug, any statements related to ongoing clinical trials for stenoparib as a monotherapy or in combination with another therapeutic candidate for the treatment of advanced ovarian cancer, or ongoing clinical trials (in Europe) for IXEMPRA® for the treatment of metastatic breast cancer, and statements relating to the effectiveness of the Company’s DRP® companion diagnostics platform in predicting whether a particular patient is likely to respond to a specific drug. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the receipt of regulatory approval for dovitinib or any of our other therapeutic candidates or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic candidates, and the risk that the current COVID-19 pandemic will impact the Company’s current and future clinical trials and the timing of the Company’s preclinical studies and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form S-1 registration statement on the Securities and Exchange Commission, available at the Securities and Exchange Commission’s website at , and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: Thomas Jensen Senior V.P. of Investor Relations investorrelations@allarity.com Investor Relations: Chuck Padala LifeSci Advisors +1 ‭(646) 627-8390‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬ chuck@lifesciadvisors.com U.S. Media Contact: Mike Beyer Sam Brown, Inc. +1 (312) 961-2502 mikebeyer@sambrown.com EU Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 tsp@carrotize.com Attachment Allarity Press Release New Board Member J. McLaughlin

WALTHAM, Mass., June 13, 2022 /PRNewswire/ -- Syndax Pharmaceuticals Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Keith A. Goldan to the role of Chief Financial Officer, effective immediately. Mr. Goldan, who brings to Syndax nearly thirty years of leadership and operational experience at several pharmaceutical, biotechnology, and medical technology companies, most recently served as Chief Financial Officer at Optinose®, where he helped build the infrastructure to support the launch of XHANCE® (fluticasone propionate) in the United States. As Chief Financial Officer at Syndax, Mr. Goldan will oversee corporate finance and accounting, financial strategy, and investor relations. "It is a pleasure to welcome Keith to the Syndax team at this exciting time for the Company," said Michael A. Metzger, Chief Executive Officer. "Keith's experience as an accomplished CFO with deep financial and operational expertise along with a solid track record of building and financing successful biopharmaceutical companies will be invaluable as we scale to a fully-integrated commercial stage company." "I look forward to joining the highly motivated team at Syndax and contributing to future progress," said Mr. Goldan. "Syndax is well positioned to achieve its strategic goals with multiple pivotal readouts next year for revumenib and axatilimab, both of which have significant commercial potential as first- and best-in-class therapies in areas of clear unmet need, and meaningful expansion opportunities into earlier lines of therapy and additional indications." Mr. Goldan has served as Chief Financial Officer of numerous private and public biopharmaceutical companies from early stage through commercial stage, including Optinose, Fibrocell, NuPathe, PuriCore plc, and Biosyn. During his career, he led the successful execution of multiple initial public offerings and follow-on equity, rights, private placement, and debt offerings, as well as several merger and acquisition transactions. Mr. Goldan received a B.S. in Finance from the Robert H. Smith School of Business at the University of Maryland and an M.B.A. from the Wharton School at the University of Pennsylvania. Syndax also announced today the appointment of Sharon Klahre to the newly created position of Vice President, Investor Relations and Communications that will report to Mr. Goldan. About Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib (SNDX-5613), a highly selective inhibitor of the Menin–MLL binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit or follow the Company on Twitter and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend," "believe" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax's product candidates, and the potential use of our product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; failure of Syndax's collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. Syndax Contact Sharon Klahre Syndax Pharmaceuticals, Inc. sklahre@syndax.com Tel 781.684.9827 Company Codes: NASDAQ-NMS:SNDX